ATE457349T1 - Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen - Google Patents

Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen

Info

Publication number
ATE457349T1
ATE457349T1 AT03792414T AT03792414T ATE457349T1 AT E457349 T1 ATE457349 T1 AT E457349T1 AT 03792414 T AT03792414 T AT 03792414T AT 03792414 T AT03792414 T AT 03792414T AT E457349 T1 ATE457349 T1 AT E457349T1
Authority
AT
Austria
Prior art keywords
hsp70
granzyme
tumor cells
peptide
cells
Prior art date
Application number
AT03792414T
Other languages
English (en)
Inventor
Gabriele Multhoff
Original Assignee
Multhoff Gabriele Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multhoff Gabriele Prof Dr filed Critical Multhoff Gabriele Prof Dr
Application granted granted Critical
Publication of ATE457349T1 publication Critical patent/ATE457349T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4613Natural-killer cells [NK or NK-T]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464476Heat shock proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6467Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50Colon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07Heat shock proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03792414T 2002-08-23 2003-08-22 Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen ATE457349T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018284 2002-08-23
PCT/EP2003/009341 WO2004018002A2 (en) 2002-08-23 2003-08-22 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells

Publications (1)

Publication Number Publication Date
ATE457349T1 true ATE457349T1 (de) 2010-02-15

Family

ID=31896833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792414T ATE457349T1 (de) 2002-08-23 2003-08-22 Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen

Country Status (13)

Country Link
US (1) US7722863B2 (de)
EP (1) EP1537204B1 (de)
JP (1) JP4699755B2 (de)
AT (1) ATE457349T1 (de)
AU (1) AU2003260452A1 (de)
CA (1) CA2535952A1 (de)
CY (1) CY1110005T1 (de)
DE (1) DE60331228D1 (de)
DK (1) DK1537204T3 (de)
ES (1) ES2340270T3 (de)
PT (1) PT1537204E (de)
SI (1) SI1537204T1 (de)
WO (1) WO2004018002A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079833A1 (de) * 2006-11-14 2009-07-22 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Zusammensetzungen und verfahren für die immuntherapie
KR101192724B1 (ko) 2010-02-04 2012-10-18 한국생명공학연구원 마이크로알엔에이의 발현을 조절하여 nk 세포를 활성화시키는 방법
CN103068973A (zh) 2010-08-20 2013-04-24 免疫创新治疗有限公司 表达Th1特性和溶细胞性质的细胞
US11559590B2 (en) 2016-07-01 2023-01-24 The General Hospital Corporation Granzyme B directed imaging and therapy
US20200237860A1 (en) * 2017-08-31 2020-07-30 Multimmune Gmbh Hsp70 based combination therapy
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
CN115305238B (zh) * 2022-09-19 2023-11-17 杭州凤喆凰生物科技有限公司 一种提高自然杀伤细胞杀伤力的成分在自然杀伤细胞培养中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
EP1007723A4 (de) * 1997-08-18 2001-11-28 Blood Res Center Methoden zur verwendung von granzymen und fixierungsmolekülen davon zur behandlung von krankheiten charkterisiert durch eine abnormale apoptose
KR20010086587A (ko) * 1998-02-27 2001-09-13 데이비드 이. 프랭크하우저 유전자 요법에 의한 염증성 세포의 자기-조절된 고사
JP4832640B2 (ja) * 1998-03-27 2011-12-07 ガブリエル ミュルソフ Hsp70タンパク質の新規使用
DE19813759C1 (de) * 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
FR2792205B1 (fr) * 1999-04-19 2001-07-27 Inst Nat Sante Rech Med Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
US20030186384A1 (en) * 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
EP1286700A2 (de) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Krebs aktivierte prodrugverbindungen
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
ES2326114T3 (es) * 2000-09-13 2009-10-01 Multimmune Gmbh Un peptido de hsp70 estimulador de la actividad de las celulas asesinas naturales (nk) y los usos del mismo.
EP1414471B1 (de) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutische Mittel mit pro-apoptotischen Proteinen

Also Published As

Publication number Publication date
WO2004018002A2 (en) 2004-03-04
WO2004018002A3 (en) 2004-06-17
CY1110005T1 (el) 2015-01-14
ES2340270T3 (es) 2010-06-01
JP2006507810A (ja) 2006-03-09
SI1537204T1 (sl) 2010-06-30
JP4699755B2 (ja) 2011-06-15
DE60331228D1 (de) 2010-03-25
DK1537204T3 (da) 2010-06-07
PT1537204E (pt) 2010-05-05
EP1537204B1 (de) 2010-02-10
AU2003260452A1 (en) 2004-03-11
US7722863B2 (en) 2010-05-25
AU2003260452A8 (en) 2004-03-11
US20060111285A1 (en) 2006-05-25
CA2535952A1 (en) 2004-03-04
EP1537204A2 (de) 2005-06-08

Similar Documents

Publication Publication Date Title
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
PT1309589E (pt) Compostos de ureia e metodos de utilizacao
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
TW200505458A (en) 1-amino 1h-imidazoquinolines
BRPI0514176A (pt) inibidores de replicação de hcv
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
EA200870164A1 (ru) Лечение вирусного гепатита
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
MEP46908A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
ATE299185T1 (de) Hemmung der expression von genen mittels dsrna
AR027114A1 (es) Proteinas insecticidas de bacillus thuringiensis
EA200700717A1 (ru) Сульфонамиды
UY28582A1 (es) Métodos para preparar derivados 7-(b (beta)-d-ribofuranosilo sustituido en 2´)-4(nr2r3)-5-(etin-1-ilo sustituido) -pirrol(2,3-d) pirimidina
EA200800763A1 (ru) Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
NO20055209L (no) Peptabody for cancerbehandling
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
CR8574A (es) Compuestos silinano como inhibidores de cisteina proteasa
CY1110005T1 (el) Γρανζυμο β ως ενας επαγωγεας αποπτωσης κυτταρων ογκων εξαρτωμενος απο ενα hsp70/hsp70 πεπτιδιο

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1537204

Country of ref document: EP